TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating female 18 years of age or older.~* Have a definite clinical diagnosis of stable plaque psoriasis involving ≥ 10% of the body surface area (BSA).~* Have a combined total lesion severity score (TLSS) of ≥ 7 for the Target Lesion.~* Have a plaque elevation score ≥ 3 of (moderate) for the Target Lesion.~* The Target Lesion must have an area of at least 5 cm².~* Have a Physicians Global Assessment (PGA) score of 3 (moderate) or 4 (severe) at baseline for the overall disease severity.~Exclusion Criteria:~* Patient has current diagnosis of other types of psoriasis other than stable plaque psoriasis (i.e. acute, guttate, erythrodermic, exfoliative or pustular psoriasis) or has psoriasis of any kind of the face or scalp that will require active treatment during the study. Nonprescription antipsoriatic shampoos will be allowed during the study when applied solely to the scalp.~* Patient has a history of psoriasis that has been unresponsive to topical corticosteroid therapy.~* In the Investigator's opinion, the patient has other dermatological conditions, such as atopic or contact dermatitis, that may interfere with the clinical assessments of the signs and symptoms of psoriasis.~* Patient has a history of allergy or sensitivity to corticosteroids or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the patient or the results of the study.~* Patient has been treated within 12 weeks (or five half lives, whichever is less) prior to the first dose of study drug with any biological therapies for psoriasis.~* Patient has received any systemic steroids within 4 weeks of the first dose of the study drug. The use of inhaled or intranasal corticosteroids is acceptable as long as usage has been stable for at least 2 weeks prior to the first dose of study drug and will be continued during the study.~* Patients who have used any topical antipsoriatic agents of any kind or any topical corticosteroids for any reason within 2 weeks prior to first use of study drug. Nonprescription antipsoriatic shampoos used only on the scalp will be allowed during the study.~* Receipt of any drug as part of a research study within 30 days prior to first dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desoximetasone Spray 0.25% (Type: EXPERIMENTAL): Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
- placebo (Type: PLACEBO_COMPARATOR): Placebo administered to affected area twice a day for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 16 years of age or older.~* Diagnosed with intra-abdominal infections or pelvic inflammatory diseases.~* Can be obtained a specimen for bacteriological efficacy assessment.~Exclusion Criteria:~* Known or suspected hypersensitivity, intolerance or contraindication to Metronidazole, Ceftriaxone sodium, or other cephem antibiotics.~* Severe renal dysfunction (creatinine clearance \< 30 mL/min.) Reference: Cockcroft-Gault calculation formula.~* Hepatic dysfunction (AST, ALT, total bilirubin \> 3 times upper limit of normal range values).~* Severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Metronidazole (Type: EXPERIMENTAL): Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) in combination with ceftriaxone sodium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage III breast cancer disease, with histological confirmation by true-cut or open-biopsy.~* Ages between 18 and 75 years old. Patients older than 70 must have an adequate quality of life to be eligible.~* Patients cannot have received previous treatment with chemotherapy, hormone therapy, radiotherapy or immune therapy.~* Performance status of 0,1, 2 Eastern Cooperative Oncology Group (ECOG).~* At least a 6 month life expectancy.~* Neutrophils \> 1500; platelets \> 100000; haemoglobin \> 10 mg/dL.~* Adequate renal and hepatic functions, with serum creatinine \< 1.2 mg/dl and total bilirubin \< 2 mg/dl.~* Adequate contraceptive methods during the study and up to 3 months after.~* Adequate cardiac function assessed by physical exam, electrocardiogram and left ventricular ejection fraction \> 55%.~Exclusion Criteria:~* Inflammatory carcinoma or stage I, II or IV breast cancer disease.~* Males.~* Active infection.~* Other neoplasms except for basal skin carcinoma or cervical in situ carcinoma adequately treated. Other previous neoplasms are allowed if diagnosed and treated more than 5 years before study registration.~* Concomitant serious disease provoking organ failure (heart, renal, hepatic, respiratory).~* Pre-existing motor or sensorial neuropathy \> grade 1.~* Inability for treatment compliance.~* History of hypersensitivity to compounds such as cremophor, cyclosporine or vitamin K.~* History of arrhythmias or congestive heart failure, even when controlled; or active cardiac blocking of second or third grade.~* History of myocardial infarction in the previous 6 months.~* Hypertension not controlled.~* Pregnant or lactating women.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Gemcitabine + Adriamycine + Paclitaxel (Type: EXPERIMENTAL): Neoadjuvant chemotherapy consisted of adriamycine 40 mg/m2, administered on day 1 as an i.v. infusion. Paclitaxel 150 mg/m2 was administered on day 2 as an i.v infusion followed by gemcitabine 2000 mg/m2 as an i.v. infusion. The three drugs were administered every two weeks for 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Effectiveness and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Treatment of Acute Pain From a Migraine Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient with a history of diagnosis of migraine with or without a warning sign (aura), that meets the criteria for a migraine, for at least 1 year~* History of migraine pain at least moderate in intensity~* Incidence of 1 to 6 headaches per month in the past year~* If female, using acceptable method of birth control~Exclusion Criteria:~* Patients with routine headaches that could be confused with migraines~* No more than 13 headache days per month in the past 6 months~* Onset of migraines after age 50~* Patients with migraines involving the eyes, chronic migraine or cluster headaches~* Patients using one or more of the following medications before study entry: more than 1 type of migraine prevention medicine in the past 6 weeks, tramadol within 30 days, vitamins/herbal remedies or non-drug-related remedies for migraine for \< 30 days, St. John's Wort within 30 days, investigational drug in past 30 days or any other disallowed medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* over 18 years of age~* acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia~* onset of symptoms less than 6 hours~* measurable neurologic deficit (National Institutes of Health \[NIH\] Stroke Scale \>/= 1)~Exclusion Criteria:~* allergy to tetracycline antibiotics~* women of child-bearing potential~* known hepatic and/or renal insufficiency~* Thrombocytopenia~* history of intolerance to minocycline~* dizziness at the time of stroke or in the past month (by self-report)~* aphasia likely to interfere with patients ability to report adverse effects~* previous functional disability~* stuporous or comatose~* presence of another serious illness likely to confound the study~* unlikely to be available for 90 day follow-up~* severe stroke (National Institutes of Health \[NIH\] Stroke Scale \>22)~* undergoing an interventional neuro-radiological intervention in first 12 hour

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related Cataract (CTNS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical and photographic diagnosis of early or no age-related cataract~* Participants with early cataract must have at least one eligible eye with VA score 20/32 or better~* Participants with no cataract must have VA score 20/32 or better in both eyes.~Exclusion Criteria:~* Advanced cataract~* Bilateral aphakia or pseudophakia~* Any ocular disease or condition that might complicate the future evaluation of cataract~* Regular use of nutritional supplements~* Failure to take at least 75% of run-in medication~* Cancer with evidence of recurrence in the past 5 years~* Major cerebral or cardiovascular events in past 12 months~* Current participation to other clinical trials~* Any condition likely to prevent adherence to CTNS follow-up schedule

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Centrum (Type: EXPERIMENTAL): multivitamin-mineral supplement. RDA dosage. 1 tablet a day for the whole study duration.
- placebo (Type: PLACEBO_COMPARATOR): placebo pills. One tablet a day for the whole study duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes~* BMI less than 45.0 kg/m2~* Insulin naive~* Currently treated with Oral Anti-Diabetic drugs (OADs) and metformin with a HbA1c between 7.0 and 9.5% or currently treated with metformin only with a HbA1c between 7.0 and 10.0%~Exclusion Criteria:~* Any clinically significant disease other than type 2 diabetes~* Currently using daily insulin~* Thiazolidinione use or other injectable diabetes medications within the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vitamin D Supplementation on Infliximab Response in Patients With Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* moderate-to-severe CD~* Treated with Infliximab~* bio-naïve at the time of diagnosis~Exclusion Criteria:~* had recent supplementation of vitD3~* had prior or concomitant use of other biologic agent, glucocorticoid and/or immunomodulators at the time of enrollment~* pregnant~* had cognitive/developmental disorders that affected their ability to complete the study procedures~* had medical illness or therapies potentially affecting bone, nutrition or growth status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamain D (Type: None): This group of patients were supplemented with 125IU/d Vitamin D
- Control (Type: None): The other group did not receive the supplementation of 125IU/d Vitamin D

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardio-vascular Protective Effects of Wolfberry in Middle-aged and Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to give an informed consent~2. Age 50 to 75 years~3. Willing to follow the study procedures~Exclusion Criteria:~1. Significant change in weight (± 5% body weight) during the past 3 months~2. Allergy to wolfberry~3. Acute illness at the study baseline~4. Exercising vigorously over the past 3 months~5. Consistently following healthy eating pattern diet in the past 3 months~6. Smoking~7. Have an average weekly alcohol intake that above 21 units per week (males) and 14 units per week (females): 1 unit = 360 mL of beer; 150 mL of wine; 45 mL of distilled spirits)~8. Pregnant, lactating, or planning pregnancy in the next 6 months~9. Taking dietary supplements which may impact the outcome of interests (e.g. vitamin supplements, antioxidant supplement etc.)~10. Prescribed and taking antihypertensive/cholesterol-lowering/ type-2 diabetic medication which started less than 5 years prior to the intervention participation~11. Insufficient venous access to allow the blood collection

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Wolfberry with healthy diet (Type: EXPERIMENTAL): Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided specific instructions to cook and consume 15 g/day wolfberry as part of a mixed-meal.
- Healthy diet (Type: ACTIVE_COMPARATOR): Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A man or woman, aged 20 to 70, of any race who has had a heart or liver transplant~Exclusion Criteria:~* hyperparathyroidism~* Paget's disease~* hyperthyroidism~* cancer~* severe kidney disease,~* intestinal disease~* active peptic ulcer disease~* current or past treatment for osteoporosis~* pregnancy or lactation~* severe oral/dental disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Active Zoledronic Acid & Placebo Alendronate (Type: EXPERIMENTAL): Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.
- Placebo Zoledronic Acid & Active Alendronate (Type: EXPERIMENTAL): Group 2 will receive an infusion of placebo zoledronic acid during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older, female, any race~* Histologically diagnosed ovarian cancer, fallopian tube cancer or primary peritoneal cancer~* High grade (or grade 3) serous histology or known to have gBRCAmut~* Has received at least 2 previous courses of platinum-containing therapy, and has disease that was considered platinum sensitive following the penultimate (next to last) platinum course (more than 6 month period between penultimate platinum regimen and progression of disease)~* Has responded to last the platinum regimen, remains in response and is enrolled on study within 8 weeks of completion of the last platinum regimen~* ECOG 0-1~* Adequate bone marrow, kidney and liver function~Exclusion Criteria:~* Known hypersensitivity to the components of niraparib~* Invasive cancer other than ovarian cancer within 2 years (except basal or squamous cell carcinoma of the skin that has been definitely treated)~* Symptomatic uncontrolled brain metastasis~* Is pregnant or breast feeding~* Immunocompromised patients~* Known active hepatic disease~* Prior treatment with a known PARP inhibitor

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Niraparib (Type: ACTIVE_COMPARATOR): 2:1 Ratio administered once daily continuously during a 28 day cycle.
- Placebo (Type: PLACEBO_COMPARATOR): Administered once daily continuously over a 28 day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Human Fibrinogen - Pharmacokinetics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥ 6 years~* Documented congenital fibrinogen deficiency: fibrinogen deficiency manifested as afibrinogenemia with plasma fibrinogen activity and antigen at screening undetectable (i.e. \< 20 mg/dL)~* Informed consent signed by subject or legal guardian~Exclusion Criteria:~* Presence or history of hypersensitivity to Human Fibrinogen Concentrate or human plasma proteins,~* Presence or history of deep vein thrombosis, pulmonary embolism, or arterial thrombosis~* Acute bleeding~* History of esophageal varicose bleeding~* End stage liver disease (i.e. Child-Pugh score B or C)~* Planned major surgery with a need for blood transfusion during the PK blood sampling period~* Polytrauma within 1 year prior to enrollment

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Human Fibrinogen Concentrate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete